Comparative Risk of Phimosis with SGLT2 Inhibitors vs GLP-1 Receptor Agonists: A Nationwide Danish Cohort
Abstract
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) are increasingly prescribed for type 2 diabetes, yet comparative safety signals for genitourinary outcomes are underexplored. Evidence suggests low absolute risks with small relative increases for SGLT2i versus GLP-1RA, though confounding by indication remains. Pharmacoepidemiology using national registries may refine estimates.Most read articles by the same author(s)
- Hiroshi Tanaka, Emma Johnson, Telehealth-Based Diabetes Education: Outcomes from a Randomized Trial , Journal of current diabetes reports: Vol. 2 No. 6 (2025)
Similar Articles
- Anders Christensen, Mikkel Nielsen, Phimosis Incidence among Users of SGLT2i Compared with GLP-1RA: Evidence from Denmark , Journal of current diabetes reports: Vol. 2 No. 3 (2024)
You may also start an advanced similarity search for this article.